지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.95 No.3
- 발행연도
- 2018.9
- 수록면
- 147 - 151 (5page)
이용수
초록· 키워드
오류제보하기
Purpose: The proportion of liver recipients with HCV is gradually increasing in Korea. Limited data are available regarding the efficacy of direct antiviral agents (DAAs) in liver transplant recipients in Asia. We aimed to assess the efficacy and safety of DAAs in HCV-infected liver recipients in Korea.
Methods: Forty HCV-infected patients from 2 centers received DAAs in the pretransplant or posttransplant period between May 2015 and November 2016.
Results: DAA was administered in the pretransplant period in 6 patients and the posttransplant period in 34 patients. Dalastavir and asunaprevir (n = 2) and sofosbuvir/ledipasvir and ribvarin (n = 4) were used in the pretransplant period. HCV RNA was not detected before liver transplantation in all patients. Sustained virological response (SVR) at 12 and 24 weeks after liver transplantation was 100%. In the posttransplant period, 33 of 34 patients received sofosfovir-based therapy. SVR at 12 weeks in those patients was 94%. Recurrent virologic relapse developed in 2 patients because of HCC recurrence or treatment failure. Adverse events included anemia (n = 2) and abdominal discomfort (n = 1).
Conclusion: DAAs are an effective and well-tolerated treatment for HCV-infected recipients in Korea.
Methods: Forty HCV-infected patients from 2 centers received DAAs in the pretransplant or posttransplant period between May 2015 and November 2016.
Results: DAA was administered in the pretransplant period in 6 patients and the posttransplant period in 34 patients. Dalastavir and asunaprevir (n = 2) and sofosbuvir/ledipasvir and ribvarin (n = 4) were used in the pretransplant period. HCV RNA was not detected before liver transplantation in all patients. Sustained virological response (SVR) at 12 and 24 weeks after liver transplantation was 100%. In the posttransplant period, 33 of 34 patients received sofosfovir-based therapy. SVR at 12 weeks in those patients was 94%. Recurrent virologic relapse developed in 2 patients because of HCC recurrence or treatment failure. Adverse events included anemia (n = 2) and abdominal discomfort (n = 1).
Conclusion: DAAs are an effective and well-tolerated treatment for HCV-infected recipients in Korea.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Hepatitis C Virus and Antiviral Drug Resistance
Gut and Liver
2016 .01
-
Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
Clinical and Molecular Hepatology
2018 .01
-
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
Clinical and Molecular Hepatology
2020 .01
-
Treatment Strategy on Hepatitis C Treatment In Liver Transplant Settings
Clinical Transplantation and Research
2016 .01
-
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
Journal of Korean Medical Science
2019 .01
-
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
Gut and Liver
2017 .01
-
Outcomes of Liver Transplant Recipient with Autoimmune Hepatitis
대한외과학회 학술대회 초록집
2022 .05
-
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
Clinical and Molecular Hepatology
2019 .01
-
Treatment Outcomes of HCV Infection in People Living with HIV: A Case Series from a Single Center in Korea
Infection and Chemotherapy
2024 .09
-
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
Clinical and Molecular Hepatology
2021 .01
-
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study
Journal of Korean Medical Science
2021 .01
-
Outcomes for patients with HCV after liver transplantation in Korea : a multicenter study
Annals of Surgical Treatment and Research
2015 .12
-
HCV treatment focusing on LT candidates/recipients
한국간담췌외과학회 학술대회지
2016 .04
-
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
Clinical and Molecular Hepatology
2019 .01
-
The early rehabilitation program for Liver transplant recipients
대한외과학회 학술대회 초록집
2017 .11
-
[Vascular Surgery / Transplantation] Long-term Clinical Outcomes and Predictive Factors for Living-Donor Liver Transplant Recipients with Acute Liver Failure
대한외과학회 학술대회 초록집
2022 .11
-
Drug-drug interactions with direct-acting antivirals ? less is more
Clinical and Molecular Hepatology
2021 .01
-
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Clinical and Molecular Hepatology
2024 .07
-
Survival Outcome of Split Liver Transplantation Compared to That of Whole Liver Transplantation : Concern of Donor Weight to Recipient Weigh Ratio in Adult Recipients
대한외과학회 학술대회 초록집
2017 .11
-
Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
Gut and Liver
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2018-514-003396825